Chemomab Therapeutics up as liver fibrosis drug meets mid-stage study goals

Chemomab Therapeutics

03/01/2023 16:14

(Updates)
    ** Shares  CMMB.O  of Israel-based drug developer Chemomab
Therapeutics Ltd soar 67.2% to hit $5.35 in the opening trade of
2023 - stock among top performers across U.S. exchanges
    ** Stock sees best day since April 2021
    ** Company says investigational drug meets goals in
mid-stage study in non-alcoholic steatohepatitis (NASH) patients
    ** Drug continues to appear safe and was well-tolerated when
administered under the skin - CMMB
    ** Patients administered with the drug showed greater
improvements than the placebo group for liver fibrosis, or
scarring in the liver tissues, company says
    ** NASH is a type of fatty liver disease, characterized by
inflammation of liver due to fat accumulation 
    ** Stock declined 53.6% in 2022
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com))